We’re looking forward to attending Bio-Neuroscience 2026 in Amsterdam, Netherlands, from February 24th - 26th. With new discoveries, technologies, and biomarkers, the time for central nervous system (CNS) neuroscience drug development is now. Join us in exploring the latest trends and treatment strategies. Come connect with Biocytogen representatives to learn about how we can support and enhance your drug development journey.
What is Bio-Neuroscience 2026?
Founded in 2024, Bio-Neuroscience has already established itself as a major science, business, innovation, and partnering event within the CNS neuroscience drug development sector. This three day, premier summit is the perfect opportunity to network with high-level thought leaders, senior decision-makers, and key stakeholders. By collaborating together, we can drive meaningful improvements in healthcare outcomes and create positive impacts on society.
Event Overview
Date: February 24th - 26th, 2026
Venue: Hotel Jakarta Javakade 766, 1019 SH Amsterdam, Netherlands
Event Schedule
For more information, please refer to the event program.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Amsterdam, Netherlands!
